Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a global pharmaceutical sourcing and distribution services company. Valued at a market cap of $55 billion, the company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions.

Companies valued at $10 billion or more are generally described as “large-cap stocks”, and Cencora fits this description perfectly. The company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. 

Cencora stock dropped 8.2% from its 52-week high of $309.35. Shares of COR have gained 11.5% over the past three months, surpassing the broader Dow Jones Industrials Average's ($DOWI) marginal decline.

On a YTD basis, COR stock has climbed 26.4%, significantly outperforming DOWI’s marginal increase. In addition, shares of Cencora have advanced 20.6% over the past 52 weeks, notably outpacing the Dow Jones’ 10.2% rise over the same time frame. 

Since mid-January, the stock has climbed above its 50-day and 200-day moving averages.

Cencora stock climbed 4.7% following the release of its solid Q2 2025 results on May 7. The company reported revenue of $75.5 billion, up 10.3% year-over-year, driven primarily by an 11.4% increase in revenue from the U.S. Healthcare Solutions segment. The revenue figure surpassed Street expectations of $74.8 billion. Adjusted EPS came in at $4.42, marking a 20.1% increase from the year-ago quarter and exceeding consensus estimates by 8.3%. Additionally, the company has raised its full-year 2025 guidance, now expecting adjusted EPS to range between $15.70 and $15.95. 

In contrast, rival Cardinal Health, Inc. (CAH) has outpaced COR stock. CAH stock has gained 29.9% on a YTD basis and soared 55.9% over the past 52 weeks.

Due to the stock’s strong performance relative to the Dow, analysts have a bullish outlook. With 15 analysts covering the stock, the consensus rating is “Strong Buy,” and it is currently trading below the mean price target of $323.93.